GC Green Cross MS Receives Approval for Dengue Virus Antibody Diagnostic Kit Export
Innovative Dengue Fever Diagnostic Kit Provides Rapid Results
GC Green Cross MS, a leading medical solutions provider, announced on the 19th that it has received permission from the Ministry of Food and Drug Safety to export its groundbreaking ‘GENEDIA W Dengue NS1 Ag’ rapid antigen test and ‘GENEDIA W Dengue IgM/IgG Ab’ antibody test. These cutting-edge diagnostic tools utilize a similar principle to the widely-adopted COVID-19 rapid diagnostic kit, enabling swift and accurate detection of the dengue virus.
Utilizing just a blood sample, the dengue fever diagnostic kit can deliver results within an impressive 20-minute timeframe. Furthermore, it is capable of diagnosing all four dengue virus serotypes, setting it apart from alternative solutions available in the market. In extensive clinical sample testing, GC Green Cross MS confirmed significantly superior sensitivity and accuracy compared to other leading companies.
Dengue fever, akin to the Zika virus, is a prominent viral febrile disease transmitted primarily by Aedes aegypti mosquitoes, prevalent in tropical and subtropical regions. Differential diagnosis becomes essential due to the overlapping symptoms with other mosquito-borne diseases like chikungunya.
As global warming and climate change continue to escalate, the risk of international spread of mosquito-borne diseases has soared, emphasizing the utmost importance of effective quarantine and accurate diagnosis. With this export license acquisition, GC Green Cross MS foresees a surge in demand for their mosquito-borne infection virus diagnostic kit, especially considering the rapid increase of dengue fever cases in Southeast Asia and South America.
An official spokesperson for GC Green Cross MS stated, “In addition to dengue fever, our dedicated team is actively involved in the development of follow-on products to tackle other mosquito-borne infectious diseases.” The company’s commitment to addressing crucial healthcare challenges further amplifies its impact in the global medical landscape.
Dengue virus antibody diagnostic kit. Photo/GC Green Cross
GC Green Cross MS announced on the 19th that it has received permission from the Ministry of Food and Drug Safety to export the ‘GENEDIA W Dengue NS1 Ag’ rapid antigen test and the ‘GENEDIA W Dengue IgM/IgG Ab’ antibody test.
A similar principle to the rapid COVID-19 diagnostic kit was applied to this dengue fever diagnostic kit.
Dengue fever can be diagnosed within 20 minutes through a blood sample, and all four dengue virus serotypes can be diagnosed. In in-house clinical sample testing, we confirmed higher sensitivity and accuracy compared to other companies.
Dengue fever, like Zika virus, is a representative viral febrile disease transmitted by Aedes aegypti mosquitoes, mainly in tropical and subtropical regions. A differential diagnosis is required as the symptoms are similar to other mosquito-borne diseases such as chikungunya.
Recently, with the acceleration of global warming and climate change, the risk of international spread of mosquito-borne diseases has increased, increasing the importance of quarantine and diagnosis.
The GC MS official said, “Recently, the dengue fever virus has spread mainly in Southeast Asia and South America, and the number of infected people is increasing rapidly. With the acquisition of this export license, we expect an increase rapid sales in the mosquito-borne infection virus diagnostic kit market.” he did
He continued, “In addition to dengue fever, the development of follow-on products for mosquito-borne infectious diseases is underway.”
#Green #Cross #permission #export #dengue #fever #rapid #diagnostic #kit